LTR Pharma has signed a term sheet with Strive Specialties, a United States personalised medicine and 503A pharmacy for ROXUS®.  

This establishes the pharmacy fulfilment infrastructure required to supply ROXUS in the US and follows our announcement earlier this week that Shed Holdings, a direct-to-consumer (DTC) telehealth platform, will be a US distributor for this novel intranasal spray. 

Our intention is to a supply ROXUS through a multi-channel commercialisation strategy incorporating telehealth, pharmacy fulfilment and healthcare provider networks. Forming relationships with Strive and Shed are crucial for de-risking our approach – right across the US. 

 We are ticking off key milestones in our commercialisation strategy for the world’s largest erectile dysfunction market and now moving rapidly towards market entry.  

Click here to read today’s ASX release.